Italian antitrust authorities are suspecting drug giants Novartis and Roche of a cartel and have launched an investigation into the matter, according to reports. The Italian Competition Authority is looking into whether the companies colluded to keep a drug off the shelves to leave space for a more expensive drug. Reports say the companies worked to keep Avastin, a drug to tread wet age related macular degeneration, off shelves to promote Lucentis, a more expensive but approved drug. Two complaints over the matter were filed to authorities by a private healthcare association and the Italian Opthalmological Society. The two companies in question are based in Switzerland.
Featured News
Bipartisan Senators Reintroduce Bill to Curb Use of Non-Competes
Jun 12, 2025 by
CPI
Senate Bill Would Shield AI Developers From Civil Liability In Certain Uses of Their Tools
Jun 12, 2025 by
CPI
FTC Considers Political Content Clause in Omnicom-Interpublic Merger Review
Jun 12, 2025 by
CPI
Female Athletes Challenge NCAA $2.7 Billion Settlement, Citing Title IX Concerns
Jun 12, 2025 by
CPI
Judge Rules Amazon Must Face Audiobook Antitrust Suit from Independent Authors
Jun 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros